These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 39250424)

  • 1. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.
    Collinson F; Royle KL; Swain J; Ralph C; Maraveyas A; Eisen T; Nathan P; Jones R; Meads D; Min Wah T; Martin A; Bestall J; Kelly-Morland C; Linsley C; Oughton J; Chan K; Theodoulou E; Arias-Pinilla G; Kwan A; Daverede L; Handforth C; Trainor S; Salawu A; McCabe C; Goh V; Buckley D; Hewison J; Gregory W; Selby P; Brown J; Brown J;
    Health Technol Assess; 2024 Aug; 28(45):1-171. PubMed ID: 39250424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
    Brown JE; Royle KL; Gregory W; Ralph C; Maraveyas A; Din O; Eisen T; Nathan P; Powles T; Griffiths R; Jones R; Vasudev N; Wheater M; Hamid A; Waddell T; McMenemin R; Patel P; Larkin J; Faust G; Martin A; Swain J; Bestall J; McCabe C; Meads D; Goh V; Min Wah T; Brown J; Hewison J; Selby P; Collinson F;
    Lancet Oncol; 2023 Mar; 24(3):213-227. PubMed ID: 36796394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer.
    Collinson FJ; Gregory WM; McCabe C; Howard H; Lowe C; Potrata D; Tubeuf S; Hanlon P; McParland L; Wah T; Selby PJ; Hewison J; Brown J; Brown J
    BMC Cancer; 2012 Dec; 12():598. PubMed ID: 23241439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
    Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
    Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.
    Fleeman N; Houten R; Nevitt S; Mahon J; Beale S; Boland A; Greenhalgh J; Edwards K; Maden M; Bhattacharyya D; Chaplin M; McEntee J; Chow S; Waddell T
    Health Technol Assess; 2024 Aug; 28(49):1-190. PubMed ID: 39252678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
    Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
    Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT.
    Scarborough M; Li HK; Rombach I; Zambellas R; Walker AS; McNally M; Atkins B; Kümin M; Lipsky BA; Hughes H; Bose D; Warren S; Mack D; Folb J; Moore E; Jenkins N; Hopkins S; Seaton RA; Hemsley C; Sandoe J; Aggarwal I; Ellis S; Sutherland R; Geue C; McMeekin N; Scarborough C; Paul J; Cooke G; Bostock J; Khatamzas E; Wong N; Brent A; Lomas J; Matthews P; Wangrangsimakul T; Gundle R; Rogers M; Taylor A; Thwaites GE; Bejon P
    Health Technol Assess; 2019 Aug; 23(38):1-92. PubMed ID: 31373271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer.
    Mehanna H; McConkey CC; Rahman JK; Wong WL; Smith AF; Nutting C; Hartley AG; Hall P; Hulme C; Patel DK; Zeidler SV; Robinson M; Sanghera B; Fresco L; Dunn JA
    Health Technol Assess; 2017 Apr; 21(17):1-122. PubMed ID: 28409743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of surgical or non-surgical management for non-acute anterior cruciate ligament injury: the ACL SNNAP RCT.
    Beard DJ; Davies L; Cook JA; Stokes J; Leal J; Fletcher H; Abram S; Chegwin K; Greshon A; Jackson W; Bottomley N; Dodd M; Bourke H; Shirkey BA; Paez A; Lamb SE; Barker KL; Phillips M; Brown M; Lythe V; Mirza B; Carr A; Monk P; Areia CM; O'Leary S; Haddad F; Wilson C; Price A;
    Health Technol Assess; 2024 Jun; 28(27):1-97. PubMed ID: 38940695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
    Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
    Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation.
    Mackenzie IS; Hawkey CJ; Ford I; Greenlaw N; Pigazzani F; Rogers A; Struthers AD; Begg AG; Wei L; Avery AJ; Taggar JS; Walker A; Duce SL; Barr RJ; Dumbleton JS; Rooke ED; Townend JN; Ritchie LD; MacDonald TM;
    Health Technol Assess; 2024 Mar; 28(18):1-55. PubMed ID: 38551218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of two speech and language approaches on speech problems in people with Parkinson's disease: the PD COMM RCT.
    Sackley CM; Rick C; Brady MC; Burton C; Jowett S; Patel S; Woolley R; Masterson-Algar P; Nicoll A; Smith CH; Abdali Z; Ives N; Beaton G; Dickson S; Ottridge R; Nankervis H; Clarke CE;
    Health Technol Assess; 2024 Oct; 28(58):1-141. PubMed ID: 39364774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.
    Coyle V; Forde C; Adams R; Agus A; Barnes R; Chau I; Clarke M; Doran A; Grayson M; McAuley D; McDowell C; Phair G; Plummer R; Storey D; Thomas A; Wilson R; McMullan R
    Health Technol Assess; 2024 Mar; 28(14):1-101. PubMed ID: 38512064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shockwave lithotripsy compared with ureteroscopic stone treatment for adults with ureteric stones: the TISU non-inferiority RCT.
    Dasgupta R; Cameron S; Aucott L; MacLennan G; Kilonzo MM; Lam TB; Thomas R; Norrie J; McDonald A; Anson K; N'Dow J; Burgess N; Clark CT; Keeley FX; MacLennan SJ; Starr K; McClinton S
    Health Technol Assess; 2022 Mar; 26(19):1-70. PubMed ID: 35301982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
    Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
    Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT.
    Wittmann M; Smith IL; Brown ST; Berekméri A; Vargas-Palacios A; Sunderland L; Barker A; Cowdell F; Ersser S; Gilberts R; Green C; Hampton P; Smith C; Nixon J
    Health Technol Assess; 2024 Oct; 28(59):1-123. PubMed ID: 39364555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.
    Duffy L; Clarke CS; Lewis G; Marston L; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Mangin D; Moore M; Nazareth I; Wiles N; Bacon F; Bird M; Brabyn S; Burns A; Donkor Y; Hunt A; Pervin J; Lewis G
    Health Technol Assess; 2021 Nov; 25(69):1-62. PubMed ID: 34842135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.
    Moakes CA; Bradbury AW; Abdali Z; Bate GR; Hall J; Jarrett H; Kelly L; Kigozi J; Lockyer S; Meecham L; Patel S; Popplewell M; Slinn G; Deeks JJ;
    Health Technol Assess; 2024 Oct; 28(65):1-72. PubMed ID: 39397484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.